Journal of Medicinal Chemistry · 2019 · 31 citations · 31 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationLigand BindingLigand-based DesignLipophilicity OptimizationMolecular DockingPotency OptimizationStructure-activity Relationship AnalysisDirected MutagenesisLipophilic Ligand EfficiencyLow-energy ConformersMedicinal Chemistry ApplicationsMolecular Property-based DesignSelectivity Profile OptimizationStructure-activity Relationship ModelingStructure-based Ligand Design
Using structure- and ligand-based design principles, a novel series of piperidyl chromane arylsulfonamide Nav1.7 inhibitors was discovered. Early optimization focused on improvement of potency through refinement of the low energy ligand conformation and mitigation of high in vivo clearance. An in vitro hepatotoxicity hazard was identified and resolved through optimization of lipophilicity and lipophilic ligand efficiency to arrive at GNE-616 (24), a highly potent, metabolically stable, subtype selective inhibitor of Nav1.7. Compound 24 showed a robust PK/PD response in a Nav1.7-dependent mouse model, and site-directed mutagenesis was used to identify residues critical for the isoform selectivity profile of 24.
31
<i>WinGX</i>and<i>ORTEP for Windows</i>: an update
Louis J. Farrugia · Journal of Applied Crystallography · 2012 · 11.8K citations
Improved protein–ligand docking using GOLD
Marcel L. Verdonk, Jason C. Cole, Michael J. Hartshorn et al. · Proteins Structure Function and Bioinformatics · 2003 · 3K citations · Full text
An SCN9A channelopathy causes congenital inability to experience pain
James J. Cox, Frank Reimann, Adeline K. Nicholas et al. · Nature · 2006 · 1.6K citations · Full text